Bioxodes annonce la
Bioxodes annonce la recommandation positive du DMC pour son essai de phase 2a dans le traitement des AVC hémorragiques avec BIOX-101
August 21, 2024 02:30 ET | Bioxodes
 Le Comité de surveillance des données (DMC, Data Monitoring Committee) a recommandé la poursuite de l’étude après l’examen planifié des données provenant des 8 premiers patients  L’analyse des...
Bioxodes reports pos
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
August 21, 2024 02:30 ET | Bioxodes
 Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients  Interim data from 16 patients scheduled around the end of 2024 ...
tx.png
Release Therapeutics Secures CHF 3.3 Million in Seed Funding
August 06, 2024 04:00 ET | Release Therapeutics SA
Release Therapeutics Secures CHF 3.3 Million in Seed Funding following first preclinical results in metachromatic leukodystrophy.
Bioxodes franchit un
Bioxodes franchit une première étape dans le recrutement de patients pour son essai de phase 2a dans le traitement des hémorragies intracérébrales avec BIOX-101
June 27, 2024 02:30 ET | Bioxodes
 Candidat médicament « first-in-class » évalué chez les huit premiers patients Gosselies (Belgique), le 27 juin 2024 – Bioxodes SA, société biopharmaceutique en phase clinique développant de...
Bioxodes meets first
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
June 27, 2024 02:30 ET | Bioxodes
 First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for...
L'Office européen de
L'Office européen des brevets notifie Bioxodes de son intention de délivrer un brevet offrant une large protection à son actif principal dans le traitement des thrombo-inflammations
May 16, 2024 03:04 ET | Bioxodes
Gosselies (Belgique), le 16 mai 2024 – Bioxodes SA, société biopharmaceutique de stade clinique développant de nouvelles thérapies dédiées à la prévention et au traitement de maladies thrombotiques et...
Bioxodes-Logo_Fond transparent.png
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
May 16, 2024 03:04 ET | Bioxodes
Gosselies (Belgium), May 16, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases,...
MicrosoftTeams-image (5).png
USD 44 Bn Medical Foods Market to Grow at a CAGR of 7.5% During 2023 to 2031 | Transparency Market Research
March 29, 2023 15:30 ET | Transparency Market Research
Wilmington, Delaware, United States, March 30, 2023 (GLOBE NEWSWIRE) -- According to market research conducted by TMR, the global medical foods industry was valued at USD 23.0 Bn in 2022 and is...
ab2bio logo.png
AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH
March 07, 2023 03:00 ET | AB2 Bio Ltd
Topline pivotal Phase 3 results expected during second half of 2023Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne...
Figure 1
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD
March 06, 2023 08:30 ET | Novelmed Therapeutics Inc
---Single therapy for multiple forms of Age-Related Macular Degeneration (AMD) NM3086 is a highly potent Alternative Pathway (AP) blocker that does not affect the Classical Pathway (CP).Dysfunction...